Latest filing published 15 May 2025 for Catalyst Pharmaceuticals, INC., €612k.
Gary Ingenito, listed as senior executive, appears in our data through filings on Catalyst Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 51 filings; the first trade dates from 20 November 2019 and the latest from 14 May 2025.
No open-market purchase appears, only 20 sales worth €19.0M. Other entries cover 6 share grants and 25 option exercises. In 2025 alone, the filings show no purchases and 4 sales.
The latest filing, published on 15 May 2025, reports an open-market sale of €4.2M in Catalyst Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations